242 completed, 57 unknown, 19 terminated, 12 recruiting. 357 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 357 | Completed 242, Unknown 57, Terminated 19, Recruiting 12, Withdrawn 12, Not yet recruiting 7, Active not recruiting 5, Enrolling by invitation 2, Suspended 1 |
Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 178 | 2026-11-01 | 2026-11-05 |
| Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia inclisiran, SOC - Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 300 | 2026-10-31 | 2026-10-30 |
| GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis Semaglutide, Placebo (Normal Saline) - Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 396 | 2026-09-01 | 2026-06-01 |
| Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome bempedoic acid, Ezetimibe, High-Intensity Statin Therapy - Acute Coronary Syndromes, Dyslipidemia | Phase 4 | Recruiting | Taipei Medical University Hospital | 400 | 2026-08-26 | 2026-09-17 |
| Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy - Coronary Artery Disease, Hyperlipidaemia | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 100 | 2026-08-01 | 2026-08-13 |
| A Post-Marketing Clinical Trial of Pemafibrate in Patients ο½—ith Hypercholesterolemia and Inadequate Response to Statins Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day, Placebo - Hypercholesterolemia | Phase 4 | Recruiting | Kowa Company, Ltd. | 120 | 2026-07-01 | 2026-07-13 |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV Tirzepatide - Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease | Phase 4 | Enrolling by invitation | National Taiwan University Clinical Trial Center | 60 | 2026-06-25 | 2026-07-20 |
| Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 4 | Recruiting | University Medical Centre Ljubljana | 60 | 2026-05-18 | 2026-06-02 |
| Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome Atorvastatin 40 Mg Oral Tablet, Ezetimibe 10 mg, Bempedoic Acid 180 MG Oral Tablet - Acute Coronary Syndromes (ACS), Hypercholesterolemia | Phase 4 | Not yet recruiting | Punjab Institute of Cardology | 120 | 2026-05-01 | 2026-04-09 |
| Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE), Standard Care (in control arm) - Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced | Phase 4 | Recruiting | Jianyin Zhou | 180 | 2026-01-18 | 2026-07-22 |
| Yangxin Dawayimixike Honey Paste for Carotid Atherosclerotic Plaque With Dyslipidemia: A Randomized Controlled Clinical Study Yangxin Dawayimixike Honey Paste, Yangxin Dawayimixike Honey Paste placebo - Dyslipidemia, Carotid Atherosclerotic Plaques | Phase 4 | Not yet recruiting | Xinjiang Uygur Pharmaceutical Co., Ltd. | 422 | 2026-01-01 | 2026-01-02 |
| Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol Rosuvastatin + Ezetimibe, Bempedoic Acid + Ezetimibe, Rosuvastatin + Ezetimibe + Bempedoic Acid - Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol | Phase 4 | Completed | Bahria University | 126 | 2026-01-01 | 2026-10-20 |
| Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia Educational Material, Standard of care - Atherosclerotic Cardiovascular Disease | Phase 4 | Recruiting | Novartis Pharmaceuticals | 326 | 2025-11-26 | 2026-05-04 |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo) - Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | Phase 4 | Recruiting | Duke University | 6000 | 2025-07-23 | 2026-10-29 |
| Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study) early time restricted Mediterranean diet, Mysimba - Diabetes Mellitus, Type 2, Liver Fibrosis | Phase 4 | Enrolling by invitation | Carmen Dietvorst | 70 | 2025-04-14 | 2026-04-21 |
| A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan Bempedoic acid 180 mg tablet - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 4 | Completed | Daiichi Sankyo | 180 | 2025-04-01 | 2025-12-08 |
| LATAM LOWERS LDL-C Usual care, KJX839 - Hypercholesterolaemia | Phase 4 | Recruiting | Novartis Pharmaceuticals | 520 | 2025-02-11 | 2025-12-30 |
| Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population Atorvastatin 10 mg and ezetimibe 10 mg, Atorvastatin 20 mg - Hyperlipidemia (E.G., Hypercholesterolemia) | Phase 4 | Withdrawn | Dr. Md. Alimur Reza | 2025-02-01 | 2026-10-07 | |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 4 | Active not recruiting | Duke University | 130 | 2024-12-16 | 2026-07-29 |
Showing 20 of 357. Sign in to see all of them.
Hypercholesterolemia (148) · Hyperlipidemias (71) · Diabetes Mellitus, Type 2 (41) · Hypertension (38) · Hypertriglyceridemia (35) · Diabetes Mellitus (32) · Atherosclerosis (31) · Cardiovascular Diseases (30) · Coronary Artery Disease (26) · Coronary Disease (16) · Insulin Resistance (15) · HIV Infections (13) · Hyperlipoproteinemia Type II (12) · Metabolic Syndrome (11)
Nutritional and Metabolic Diseases (356) · Metabolic Diseases (355) · Lipid Metabolism Disorders (349) · Hyperlipidemias (173) · Vascular Diseases (117) · Cardiovascular Diseases (104) · Glucose Metabolism Disorders (80) · Endocrine System Diseases (68) · Arterial Occlusive Diseases (57) · Arteriosclerosis (57) · Myocardial Ischemia (51) · Heart Diseases (50) · Pathological Conditions, Signs and Symptoms (43) · Diabetes Mellitus (34)
Atorvastatin (70) · Ezetimibe (50) · Rosuvastatin Calcium (46) · Simvastatin (34) · Fenofibrate (20) · Omacor (14) · evolocumab (14) · pitavastatin (14) · Niacin (13) · Pravastatin (13) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (12) · Amlodipine (11) · Ezetimibe, Simvastatin Drug Combination (11) · alirocumab (9) · Colesevelam Hydrochloride (8)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (23) · Organon and Co (19) · Yonsei University (10) · Gachon University Gil Medical Center (9) · Takeda (8) · AstraZeneca (7) · Daiichi Sankyo (7) · Novartis Pharmaceuticals (7) · Novartis (5) · Seoul National University Hospital (5) · JW Pharmaceutical (4) · Seoul National University Bundang Hospital (4) · University of Ioannina (4) · Yuhan Corporation (4) · Duke University (3)
United States (73) · South Korea (51) · China (22) · Japan (19) · Italy (15) · Spain (14) · Germany (13) · Canada (10) · Taiwan (9) · France (8) · United Kingdom (8) · Greece (7) · Belgium (6) · Brazil (6) · Israel (6)
Andrew D Carr, MD (2) · Ann-Brit E Hansen, M.D. (2) · Court Pedersen, Professor (2) · David A Cooper, MD (2) · Jan Gerstoft, M.D., DMSc (2) · Jifei Tang, MD (2) · Kevin C. Maki, PhD (2) · Lawrence Baruch, MD (2)
PMID 38018702, PMID 21297494, PMID 10069782, PMID 10323786, PMID 10367822, PMID 10529901, PMID 10593347, PMID 10946791, PMID 11009277, PMID 11339434, PMID 11558482, PMID 11781675, PMID 11849859, PMID 12379573, PMID 12652104, PMID 15249516, PMID 15329324, PMID 15364185, PMID 15505289, PMID 15611492, PMID 16310551, PMID 16404415, PMID 16749654, PMID 16893434, PMID 16923260, PMID 17011942, PMID 17190864, PMID 17407633, PMID 17578790, PMID 17626713, PMID 17635891, PMID 17668878, PMID 17711927, PMID 17804683, PMID 17827859, PMID 17898099, PMID 18070815, PMID 18172039, PMID 18312764, PMID 18332269, PMID 18398080, PMID 18404599, PMID 18413554, PMID 18519429, PMID 18545068, PMID 18559695, PMID 18653575, PMID 18762410, PMID 18955731, PMID 19060422
2015 (2), 2018 (2), 2004 (1), 2005 (1), 2016 (1), 2023 (1), K23AT002862 (1), K23HL169929 (1), R01AR071263 (1), R01DK061486 (1), R01HL063055 (1), R01HL075824 (1), R01HL096585 (1), R01MH071536 (1), R21AT003083 (1)